Aidan King
Co-Founder & Managing Partner @ Fountain Healthcare Partners
New York, United States
Aidan King is a Series A investor at Fountain Healthcare Partners in New York focused on Health Care and Biotechnology. Aidan King is based out of New York, New York and is the Co-Founder & Managing Partner of Fountain Healthcare Partners. Aidan previously worked atErmium Therapeutics as a Board Member. Aidan King attended the University College Dublin. Aidan King has been certified CFA Institute Charterholder.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Aidan King invests in
Stages Aidan King invests in
Countries Aidan King invests in
Investment Focus
Industry
- Health Care 5 (63%)
- Biotechnology 4 (50%)
- Pharmaceutical 3 (38%)
- Biopharma 1 (13%)
- Life Science 1 (13%)
Stage
- Series A 4 (50%)
- Series B 3 (38%)
- Series C 1 (13%)
Country
- United States 3 (38%)
- France 1 (13%)
- Belgium 1 (13%)
- Germany 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exciva
|
exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M / Series B / Jan 20, 2026 | |
XyloCor Therapeutics
|
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $67.5M / Series B / Jan 07, 2025 | |
Ermium Therapeutics
|
Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company isbased in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education. | $6.3M / Series A / Jun 30, 2022 | |
|
XyloCor Therapeutics
|
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $22.6M / Series A / Mar 22, 2021 | |
Syndesi Therapeutics
|
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research. | $18.6M / Series A / Feb 15, 2018 | |
Civitas Therapeutics
|
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States. | $55M / Series C / Aug 25, 2014 | |
|
Civitas Therapeutics
|
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States. | $38M / Series B / Sep 11, 2013 | |
Palyon Medical
|
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases. | $24M / Series A |
Co-Investors
About Fountain Healthcare Partners
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Fountain Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aidan King
Co-Founder & Managing Partner
|
|||
Ena Prosser
Partner
|
|||
Justin Lynch
Partner & CFO
|
|||
Manus Rogan
Co-Founder & Managing Partner
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Aidan King invest in?
Aidan King invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Aidan King last invest?
The most recent investment recorded for Aidan King closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
